Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Steven H. Marshall,Andrea M. Hujer,Andrea M. Hujer,Laura J. Rojas,Laura J. Rojas,Krisztina M. Papp-Wallace,Romney M. Humphries,Brad Spellberg,Kristine M. Hujer,Kristine M. Hujer,Emma K. Marshall,Susan D. Rudin,Susan D. Rudin,Federico Perez,Federico Perez,Brigid Wilson,Ronald B. Wasserman,Linda Chikowski,David L. Paterson,Alejandro J. Vila,David van Duin,Barry N. Kreiswirth,Henry F. Chambers,Vance G. Fowler,Michael R. Jacobs,Mark Pulse,William J. Weiss,Robert A. Bonomo +27 more
Reads0
Chats0
TLDR
In vitro activity of CAZ-AVI in combination with ATM against diverse Enterobacteriaceae possessing MBLs was demonstrated, and the data presented herein require us to carefully consider this new therapeutic combination to treat infections caused by MBL-producing Enterobacteria.Abstract:
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). Disk diffusion and agar-based antimicrobial susceptibility testing were initially performed to determine the in vitro efficacy of a unique combination of CAZ-AVI and ATM against 21 representative Enterobacteriaceae isolates with a complex molecular background that included blaIMP, blaNDM, blaOXA-48, blaCTX-M, blaAmpC, and combinations thereof. Time-kill assays were conducted, and the in vivo efficacy of this combination was assessed in a murine neutropenic thigh infection model. By disk diffusion assay, all 21 isolates were resistant to CAZ-AVI alone, and 19/21 were resistant to ATM. The in vitro activity of CAZ-AVI in combination with ATM against diverse Enterobacteriaceae possessing MBLs was demonstrated in 17/21 isolates, where the zone of inhibition was ≥21 mm. All isolates demonstrated a reduction in CAZ-AVI agar dilution MICs with the addition of ATM. At 2 h, time-kill assays demonstrated a ≥4-log10-CFU decrease for all groups that had CAZ-AVI with ATM (8 μg/ml) added, compared to the group treated with CAZ-AVI alone. In the murine neutropenic thigh infection model, an almost 4-log10-CFU reduction was noted at 24 h for CAZ-AVI (32 mg/kg every 8 h [q8h]) plus ATM (32 mg/kg q8h) versus CAZ-AVI (32 mg/kg q8h) alone. The data presented herein require us to carefully consider this new therapeutic combination to treat infections caused by MBL-producing Enterobacteriaceae.read more
Citations
More filters
Journal ArticleDOI
De nouveaux antibiotiques : oui mais pour quelles situations en réanimation ?
TL;DR: L’isolement plus fréquent, notamment dans les services de réanimation, de bactéries hautement résistantes rend malheureusement possible « the fin du miracle », c’est-à-dire le retour d’un monde sans antibiotiques.
Journal ArticleDOI
Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: A general guidance for clinical microbiology laboratories in India
TL;DR: In this article , the combination of aztreonam with ceftazidime-avibactam has gained much clinical attention mainly for MBL-producing Enterobacterales, while MBL producing P. aeruginosa and A. baumannii are likely to be resistant.
Journal ArticleDOI
A review of recent advances in the treatment of adults with complicated urinary tract infection
TL;DR: The advances in the management of complicated urinary tract infections (cUTIs) are explored in this paper , illustrating a proposed therapeutical approach to cUTIs within the antimicrobial stewardship context; evidence regarding novel antibiotics targeting MDROs.
Journal ArticleDOI
Susceptibility of Burkholderia cepacia Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients.
TL;DR: In this article , the authors assess the susceptibility of Burkholderia cepacia complex (Bcc) to ceftazidime/avibactam and standard drugs for the treatment for CF patients and determine the respective genomic determinants of resistance.
Journal ArticleDOI
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers
Thomas P. Lodise,J. Nicholas O'Donnell,Shruti M. Raja,Jeffrey T. Guptill,Smitha Zaharoff,Nyssa Schwager,Vance G. Fowler,Tatiana Beresnev,Alison Wall,Katherine Wiegand,Elisavet Serti Chrisos,Stephen J. Balevic,Henry F. Chambers +12 more
TL;DR: In this article , the authors evaluated the safety of the optimal ceftazidime-avibactam (CZA) with aztreonam (ATM) regimens identified in hollow fiber infection models of MBL-producing Enterobacterales.
References
More filters
Journal Article
Vital signs: carbapenem-resistant Enterobacteriaceae.
Jesse T. Jacob,Eili Y. Klein,Ramanan Laxminarayan,Zintars G. Beldavs,Ruth Lynfield,Alexander J. Kallen,Philip Ricks,Jonathan R. Edwards,Arjun Srinivasan,Scott K. Fridkin,J. Kamile Rasheed,David Lonsway,Sandie Bulens,Rosa Herrera,L. Clifford McDonald,Jean B. Patel,Brandi Limbago,Michael Bell,Denise M. Cardo +18 more
TL;DR: Carbapenem resistance among common Enterobacteriaceae has increased over the past decade; most CRE are associated with health-care exposures; Implications for Public Health Interventions exist that could slow the dissemination of CRE.
Journal ArticleDOI
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
David van Duin,Robert A. Bonomo +1 more
TL;DR: Ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-generation cephalosporin/β-lactamase inhibitor combinations and may prove useful in the treatment of MDR GNB infections.
Journal ArticleDOI
New Delhi Metallo-β-Lactamase-Producing Carbapenem-Resistant Escherichia coli Associated With Exposure to Duodenoscopes
Lauren Epstein,Jennifer C. Hunter,M. Allison Arwady,M. Allison Arwady,Victoria Tsai,Linda Stein,Marguerite Gribogiannis,Mabel Frias,Alice Guh,Alison S. Laufer,Stephanie R. Black,Massimo Pacilli,Heather Moulton-Meissner,J. Kamile Rasheed,Johannetsy J. Avillan,Brandon Kitchel,Brandi Limbago,Duncan MacCannell,David Lonsway,Judith Noble-Wang,Judith Conway,Craig Conover,Michael O. Vernon,Alexander J. Kallen +23 more
TL;DR: Exposure to duodenoscopes with bacterial contamination was associated with apparent transmission of NDM-producing E coli among patients at 1 hospital and facilities should be aware of the potential for transmission of bacteria including antimicrobial-resistant organisms via this route.
Journal ArticleDOI
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
TL;DR: This “renaissance” of β-lactamase inhibitors offers new hope in a world plagued by multidrug-resistant (MDR) Gram-negative bacteria.
Related Papers (5)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms
Elizabeth Temkin,Julián Torre-Cisneros,Bojana Beović,N. Benito,Maddalena Giannella,Raúl Gilarranz,Cameron J Jeremiah,Belén Loeches,Isabel Machuca,María José Jiménez-Martín,José Antonio Martínez,Marta Mora-Rillo,Enrique Navas,Michael Osthoff,J.C. Pozo,Juan Carlos Ramos Ramos,Marina Rodríguez,Miguel Sánchez-García,Pierluigi Viale,Michel Wolff,Yehuda Carmeli,Yehuda Carmeli +21 more